For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30262506.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2690.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intratumoral immunotherapy can potentially modulate the tumor microenvironment (TME) and potentiate the effects of concomitant or sequential systemic immunotherapies. Intratumoral administration of different Toll-like receptor agonists, including TLR4, can potentiate these effects through innate and adaptive immunity connection.See related article by Bhatia et al., p. 1185.
Medical subject headings
- Carcinoma, Merkel Cell
- Skin Neoplasms